Disease Overview Template

(*General Instructions – The main focus of these pages is for Associate Editors to provide context for relatedness of diseases in a category, with links to more detailed internal content. Use* [*HUGO-approved gene names and symbols*](https://www.genenames.org/) *(italicized when appropriate), [HGVS-based nomenclature for variants](https://varnomen.hgvs.org/), as well as generic names of drugs and testing platforms or assays if applicable. Additional instructions below in italicized blue text should not be included in the final page content. Please also see* [*Author Instructions*](https://ccga.io/index.php/Author_Instructions) *and* [*FAQs*](https://ccga.io/index.php/Frequently_Asked_Questions_%28FAQs%29) *as well as contact your* [*Editor-in Chief*](https://ccga.io/index.php/Leadership) *or* *Technical Support**.*)

**Primary Author(s)\***

Put your text here (*Name and affiliation; example:* Jane Smith, PhD, Institute of Genomics)

**Graphical Data Links**

Put your graphics placeholder here

**General Disease Overview / Description of Cancer Category**

Put your text here *(Instruction: Use a list of four bullet points, targeting one to three sentences for each of the following areas. Cite the current WHO Classification of Tumours and describe how this cancer category is structured within it. Define the unifying theme/features that explain why the linked disease entities fit into this cancer category. Describe how the linked disease entities are generally defined in terms of genetic content – i.e. cytogenetics, molecular, fusion gene(s), copy number alterations, etc. Define the range of ages such as “most common in the pediatric population but also rarely affects adults”.)*

EXAMPLE:

* The major classification group of "Mature B-cell Neoplasms", as described in the revised 4th edition of the WHO[manually added book reference], includes the categories: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Prolymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Hairy Cell Leukemia, and many others. Links to these and all categories as well as links to subcategories are listed below in the "WHO Classification Pages" section. In addition, significant genetic topics related to this group not currently considered a WHO-defined entity are also listed below in the "Other Related Pages" section.
* The mature B-cell neoplasms are a group of leukemias and lymphomas originating from the B-cell lineage which have developed beyond the precursor/blast stage (hence “mature”). Therefore, they often (but not always) express B-cell markers (*e.g.*, CD19, CD20, PAX-5), harbor immunoglobulin heavy chain and light chain gene rearrangements, lack markers of immaturity (*e.g.*, TdT, CD34), and lack markers of other lineages (*e.g.*, T-cell and myeloid). Morphologically, they may resemble small mature lymphocytes (e.g., chronic lymphocytic leukemia, marginal zone lymphoma, follicular lymphoma), plasma cells (e.g., plasma cell myeloma, plasmacytomas), or large transformed lymphoid cells (e.g., diffuse large B-cell lymphoma NOS).
* They represent a molecularly heterogeneous category harboring various driver alterations, including gene rearrangements (*e.g.*, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, plasma cell myeloma), missense mutations (lymphoplasmacytic lymphoma, plasma cell myeloma), and copy number gains and losses (*e.g.*, chronic lymphocytic leukemia) or virally-induced transformations (*e.g.*, Primary Effusion Lymphoma, Burkitt lymphoma).
* The majority of the mature B-cell neoplasms are seen in the older age groups; however, a few (*e.g.*, Large B-cell Lymphoma with IRF4 Rearrangement, Endemic Burkitt lymphoma) primarily occur in the pediatric population.

**WHO Classification Pages (Includes Links to Content)**

Put your link placeholder here (links will be converted using the link icon at top of page in the CCGA site) (*Note – if need help, please contact the* [*Technical Editor*](https://ccga.io/index.php/Leadership)*)*

**Other Related Pages (Includes Links to Content)**

Put your text placeholder here (links will be converted using the link icon at top of page in the CCGA site) (*Note – if need help, please contact the* [*Technical Editor*](https://ccga.io/index.php/Leadership)*)*

**Additional Information**

Put your text here

**References**

*(Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated)*

(*Instruction: If a PMID is not available, such as for a book, please include the entire reference in this section*)

BOOK EXAMPLE: Mature B-cell neoplasms, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p216-344, 2017.

**Notes**

\*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.